Brought to you by 
Abbott licenses MedImmune's MEDI-493
03 Dec 2018
Executive Summary
Abbott Laboratories has acquired exclusive rights outside of the US to MedImmune's MEDI 493 (palivizumab) to treat respiratory syncytial virus (RSV). Within the US, the company's Ross division will co-promote it with MedImmune.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Manufacturing or Supply
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott licenses MedImmune's MEDI-493
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice